Phonatory effects of inhaled corticosteroids in individuals with asthma
Abstract
Purpose. Inhaled corticosteroids (ICS) are anti-inflammatory agents commonly used for long-term asthma management. Voice problems are the most frequently reported chronic, adverse effect of ICS therapy. However, the short-term effects of ICS on phonation are not known. The purpose of the present study was to objectively examine the acute phonatory effects of the commonly prescribed ICS treatment fluticasone proprionate in high dose and low dose subject groups. Methods. Adults diagnosed with asthma prescribed a high dose (N = 6) and low dose (N = 6) ICS treatment participated in a repeated-measures design over two experimental days: ICS treatment and sham treatment. Phonation threshold pressure (PTP) and perceived phonatory effort (PPE) were collected before ICS/sham treatment; and immediately, 1-hour, and 2-hours following treatment. Results. ICS but not sham treatment increased PTP over 2-hours. However, high and low doses of ICS treatment did not demonstrate differential effects on PTP. PPE ratings were not significantly correlated with PTP. Conclusions. The increase in PTP following ICS treatment, but not sham treatment demonstrates that ICS treatment results in acute, detrimental phonatory changes in participants who do not present with overt voice problems. The observed elevated PTP levels may; therefore, indicate an emerging voice decrement prior to overt manifestations in traditional diagnostic testing.
Degree
M.S.
Advisors
Sivasankar, Purdue University.
Subject Area
Speech therapy|Pharmacy sciences
Off-Campus Purdue Users:
To access this dissertation, please log in to our
proxy server.